文献速递血液净化与透析

皮下注射阿法依泊汀生物类似药与阿法依泊汀在终末期肾病中的随机对照试验

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease.
PubMed 文献 · Kidney Int Rep · 2019-05-22

这项双盲随机对照试验在320例接受阿法依泊汀维持治疗的血液透析终末期肾病贫血患者中,比较皮下注射阿法依泊汀生物类似药(epoetin alfa-epbx)与参照药阿法依泊汀的安全性和有效性。246例进入16周维持期的患者被再次随机分配,主要终点为维持期最后4周的平均每周血红蛋白浓度和平均每周每公斤体重依泊汀剂量的组间最小二乘均值差。结果显示两种药物在疗效上等效,安全性相似。

要点

  • 皮下阿法依泊汀生物类似药与参照药在维持透析患者血红蛋白水平和依泊汀剂量上等效。
  • 两组不良事件、严重不良事件、输血和死亡发生率相似,未出现中和抗体阳性。
  • 该生物类似药可作为阿法依泊汀的替代选择用于终末期肾病贫血的维持治疗。

核心结论

  • 皮下注射阿法依泊汀生物类似药与阿法依泊汀在终末期肾病透析患者中疗效等效且安全性相似。

研究设计与样本

  • 双盲、随机对照试验,纳入320例接受阿法依泊汀维持治疗的血液透析终末期肾病贫血患者,按1:1随机分配至生物类似药或参照药组进行剂量滴定。
  • 其中246例达到稳定皮下给药的患者再次随机分配,进入16周维持期,接受每周1至3次皮下注射。

主要发现

  • 维持期最后4周,每周血红蛋白的组间最小二乘均值差为0.04 g/dl(95%CI -0.17至0.24 g/dl),每周每公斤体重依泊汀剂量的差值为-2.34 U/kg/周(95%CI -14.51至9.82 U/kg/周)。
  • 两个95%CI均落在预设等效界值内(血红蛋白±0.5 g/dl,剂量±45 U/kg/周)。
  • 生物类似药组和参照药组分别有4.0%和4.1%的患者需要输血,69.7%和70.5%报告不良事件,18.9%和27.0%报告严重不良事件,死亡分别为3例和2例。
  • 5例患者抗重组人促红细胞生成素抗体确认阳性,其中2例基线即阳性;所有患者中和抗体检测均为阴性。

关键数值与推荐

  • 等效性界值:每周血红蛋白±0.5 g/dl,每周每公斤体重依泊汀剂量±45 U/kg/周。
  • 主要终点为维持期最后4周的平均每周血红蛋白浓度和平均每周每公斤体重依泊汀剂量的组间最小二乘均值差。

临床怎么用

  • 对于接受阿法依泊汀维持治疗的血液透析终末期肾病贫血患者,可考虑使用皮下阿法依泊汀生物类似药作为替代。
  • 转换时需按稳定皮下给药方案进行剂量滴定,并监测血红蛋白和依泊汀剂量以维持等效性。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This double-blind, randomized controlled trial compared the safety and efficacy of subcutaneous epoetin alfa-epbx, an epoetin alfa biosimilar, with the reference product, epoetin alfa, in hemodialysis patients with end-stage kidney disease (ESKD) and anemia who were receiving epoetin alfa maintenance treatment. METHODS: Eligible patients (n = 320) were randomized (1:1) to subcutaneous epoetin alfa-epbx or epoetin alfa in a titration phase; patients who demonstrated stable subcutaneous dosing (n = 246) were re-randomized to receive subcutaneous epoetin alfa-epbx or epoetin alfa 1 to 3 times per week in a 16-week maintenance phase. Co-primary endpoints were least-squares mean difference between treatments in mean weekly hemoglobin concentration and mean weekly epoetin dose per kilogram body weight (BW) during the last 4 weeks of treatment in the maintenance phase. RESULTS: The least-squares mean difference (95% confidence interval [CI]) between treatments in weekly hemoglobin was 0.04 g/dl (-0.17 to 0.24 g/dl) and weekly epoetin dose/kg BW was -2.34 U/kg per week (-14.51 to 9.82 U/kg per week). The 95% CIs were contained within the prespecified equivalence margins of ±0.5 g/dl (weekly hemoglobin) and ±45 U/kg per week (weekly epoetin dose/kg BW). In the epoetin alfa-epbx and epoetin alfa groups, respectively, 4.0% and 4.1% of patients required blood transfusions, 69.7% and 70.5% reported adverse events, 18.9% and 27.0% reported serious adverse events, and 3 and 2 deaths were reported. Five patients were confirmed positive for anti-recombinant human erythropoietin antibody, 2 of whom tested positive at baseline. All patients tested negative for neutralizing antibodies. CONCLUSIONS: This comparative clinical trial demonstrated equivalence in efficacy and similar safety of subcutaneously administered epoetin alfa-epbx to epoetin alfa.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Fishbane S, Spinowitz BS, Wisemandle WA, et al. Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease. Kidney Int Rep. 2019. PMID: 31517143. doi:10.1016/j.ekir.2019.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。